



June 2, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Ltd.,**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards receipt of U.S. FDA approval for the Company's Meloxicam Capsules, 5 mg and 10 mg, to market a generic equivalent of Vivlodex® Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For LUPIN LIMITED

**RAJVARDH
AN VISHNU
SATAM**

Digitally signed by RAJVARDHAN
VISHNU SATAM
DN: c=IN, o=Personal,
postalCode=400062, st=Maharashtra,
2.5.4.20=c19d8ef961d9fa59e973a093a
4d392462532eb2f4966a762abc74700f
5375b7,
serialNumber=df8e6e9a88c796663c7
38ea230fa0e475c195726cd657a2ff09
c4242771b2a, cn=RAJVARDHAN
VISHNU SATAM
Date: 2020.06.02 15:56:23 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl- : a/a.

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Lupin Receives Approval for Meloxicam Capsules

Mumbai, Baltimore, June 02, 2020: Pharma major Lupin Limited (Lupin) announced that it has received approval for its Meloxicam Capsules, 5 mg and 10 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Vivlodex® Capsules, 5 mg and 10 mg, of Zyla Life Sciences US, Inc. The product would be manufactured at Lupin's Aurangabad facility, India, and is expected to be launched shortly.

Meloxicam Capsules, 5 mg and 10 mg, are indicated for management of osteoarthritis (OA) pain.

Meloxicam Capsules (RLD: Vivlodex®) had an annual sales of approximately USD 14 million in the U.S. (IQVIA MAT March 2020).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

Facebook: www.facebook.com/LupinWorld/

For further information or queries please contact –

Arvind Bothra Head – Investor Relations and Corporate Communications Email: arvindbothra@lupin.com Tel: +91 22 6640 8237	Manjira Sharma General Manager – Corporate Communications Email: manjirasharma@lupin.com Tel: +91 22 6640 2532
--	---

****Safe Harbor Statement***

Vivlodex® is a registered trademark of Zyla Life Sciences Corporation.